ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Kürzel: AZN Forum: Aktien Thema: Hauptdiskussion

Allein unterstützen sollte man den Mist nicht

Astra größter Mist ne bekannte die jung ist hat durch die Impfung ein Schlaganfall erlitten

23 July 2021 Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print, demonstrated one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta/Gamma variants of the SARS-CoV-2 virus.

https://www.reuters.com/article/uk-health-coronavirus-britain-vaccines-idUSKBN2ER2FO

Wednesday’s study found that two doses of Pfizer’s shot was 88% effective at preventing symptomatic disease from the Delta variant, compared to 93.7% against the Alpha variant, broadly the same as previously reported. Two shots of AstraZeneca vaccine were 67% effective against the Delta variant, up from 60% originally reported, and 74.5% effective against the Alpha variant, compared to an original estimate of 66% effectiveness.

21 July 2021 AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.

Lol die USA und die WHO werfen Pfizer/Biontech Geldgier vor und lehnen eine dritte "Booster"-Impfung von Pfizer/Biontech ab. 🤣😂

8 July 2021 AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.

Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma

https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-eu.html

6 July 2021 AstraZeneca's proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion) has achieved an important step towards completion by having cleared the European Commission review.

Sie hebt schon gut ab. Seit Anfang März von 78 bis jetzt auf 100 ist doch ganz normal

Ich hoffe das die jetzt langsam anhebt

Das sind gute Nachrichten

Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants at high risk of RSV 28 June 2021 The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.